Welcome to our dedicated page for CytoMed Therapeutics SEC filings (Ticker: GDTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CytoMed Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CytoMed Therapeutics's regulatory disclosures and financial reporting.
CytoMed Therapeutics Limited filed a report describing a public statement it issued to counter inaccurate claims about its research programs, clinical progress, and operations. The company explains that its work centers on CAR γδ T cell and iPSC-derived γδ NKT cell immunotherapies for cancer.
CytoMed states that its lead CAR γδ T cell program has regulatory approval for a first-in-human clinical trial that is ongoing at National University Hospital in Singapore. Other iPSC-derived γδ NKT cell candidates remain in preclinical development, and the company emphasizes that none of its therapies are approved for commercial use.
The company reiterates its focus on regulatory compliance, scientific rigor, transparent disclosure, and indicates it may take action against false or misleading information that could harm its reputation or stakeholders.
CytoMed Therapeutics Limited, a Singapore-based clinical stage cell therapy company, provided a new year update on its pipeline, funding and shareholder engagement. The company is advancing donor-derived gamma delta T cell and Natural Killer cell immunotherapies, including support from Enterprise Singapore for its Natural Killer cell work through subsidiary LongevityBank. Management believes it has enough resources to fund activities for at least a year and is exploring licensing, real estate asset monetisation and strategic partnerships to support the business with less dilution.
CytoMed highlighted a Memorandum of Understanding with Universiti Malaya to run a first-in-human Phase I trial of its allogeneic unmodified gamma delta T cells in no-option cancer patients in Malaysia, targeting an Investigational New Drug submission before June. This complements an ongoing Phase I CAR-T trial in Singapore, where six patients have been treated. The company also cited a recent co-authored preclinical publication with MD Anderson Cancer Center on acute myeloid leukemia and noted that its chairman intends to increase his shareholding. CytoMed is seeking shareholder feedback on a proposed scheme allowing shareholders, subject to medical approval and local rules, to use their shareholdings to access its donor-derived allogeneic unmodified gamma delta T cell therapy.
CytoMed Therapeutics Limited reported that it has signed a Memorandum of Understanding with Universiti Malaya Medical Centre in Malaysia. The parties plan to explore a multi-site, first-in-human Phase I clinical trial of CytoMed’s patented donor-derived gamma delta T cell product candidate.
The proposed trial would focus on cancer patients who have exhausted standard treatment options and would evaluate both the safety and efficacy of using gamma delta T cells sourced from healthy donors. This represents an early clinical step for CytoMed’s off-the-shelf allogeneic cell therapy approach in Malaysia.
CytoMed Therapeutics Limited reported that it has completed the acquisition of synergistic assets from TC BioPharm Limited. These T cell technology assets are intended to be enhanced and re-purposed to treat cancers in China and India, signaling a focus on cell-based cancer therapies in large Asian markets. The announcement was made through a press release dated November 18, 2025, which is attached as an exhibit to this Form 6-K.
CytoMed Therapeutics Limited furnished a Form 6-K noting it issued a press release on November 6, 2025. The update announces a non-dilutive investment for its subsidiary LongevityBank Pte Ltd from ICH Capital Pte Ltd and provides updates on its new China strategy.
The press release is included as Exhibit 99.1 titled “CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy.”
CytoMed Therapeutics Limited reported that its Executive Chairman and substantial shareholder, Mr. Choo Chee Kong, increased his shareholding through recent open‑market purchases of 105,824 shares.
According to the accompanying press release title, his effective ownership is now 21.95%. The update was furnished on a Form 6‑K dated October 22, 2025.
CytoMed Therapeutics Limited reported that it has submitted a cash bid of an undisclosed sum for a potential acquisition of selected, potentially synergistic assets of TC BioPharm Limited. The announcement was made on October 14, 2025, and notes that TC BioPharm entered administration on October 2, 2025.
The update signals an interest in expanding CytoMed’s capabilities through asset acquisition, though terms and valuation were not disclosed. A related press release is furnished as Exhibit 99.1. As this is a bid for assets rather than a completed transaction, outcomes and financial effects depend on subsequent developments and any negotiated terms.
CytoMed Therapeutics Limited filed a Form 6-K to share that it issued a press release about new collaborative research with The University of Texas MD Anderson Cancer Center. The publication describes research demonstrating the potential of CytoMed’s allogeneic γδ T cells to treat acute myeloid leukemia, a type of blood cancer. The filing itself mainly serves to make this scientific update available to investors and includes the full press release as an exhibit.
CytoMed Therapeutics Limited furnished a Form 6-K providing its unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025, together with management’s discussion and analysis of financial condition and results of operations for the same period.
The company also scheduled a Zoom conference call for the investment community on October 2, 2025 at 10 a.m. ET to discuss these financial results.
CytoMed Therapeutics Ltd (GDTC) filed a Form 144 notifying a proposed sale of 54,644 ordinary shares with an aggregate market value of $102,731 to be sold approximately on 09/23/2025 on NASDAQ. The filer reports total outstanding shares of 11,733,712. The securities were originally acquired by share subscription on 04/22/2021 (payment noted as cash on 04/20/2021) totaling 711,822 shares at acquisition. The filing also lists prior open-market sales by the same account during Aug–Sep 2025 totaling 26,838 shares sold over multiple dates, with individual gross proceeds reported per sale. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.